knowledge -WSS

knowledge

author：Wikipedia 2025-08-06 04:47:22 - browse：7879

Pascal Soriot 2019 — Pascal Soriot has served as CEO of AstraZeneca since 2012. Win McNamee/Getty Images

CAMBRIDGE, England — On a bit of a roll, AstraZeneca on Tuesday laid out ambitious growth goals for the rest of the decade, seeking to build on its momentum in fields like oncology as it said it would nearly double its revenue to $80 billion by 2030.

Hitting such a target would depend on the launch of 20 new medicines and continued growth of its cancer and rare disease therapies, as well as other drugs. It would also require outpacing the targets laid out by AstraZeneca’s large pharma peers.

But at an investor day here at the company’s shiny new Discovery Centre, CEO Pascal Soriot opened his presentation by bringing up the goal set by the company a decade ago — $45 billion in revenue by 2023. The company faced some declines early in that period, but after surging in the past few years, it hit that target, bringing in $45.8 billion last year. Its recent growth has also propelled the company’s share price.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Sports medicine is finally prioritizing gender equality
Next article： Getting Alzheimer's drug Leqembi to patients can be a challenge

WSS

Sen. Paul opposes bill to ban Chinese biotechs

MassMutual is introducing free genetic testing for members

Amylyx ALS drug failure raises questions and concerns

FTC falls short on scrutinizing hospital mergers, study says

CDC marks new Covid

After traumatic brain injury, life support decisions can use more time

knowledge

knowledge

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

leisure time

Hollywood unions extend contract negotiations for actors

What it’s like to watch children die of measles

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Novo Nordisk obesity pill bests Wegovy in early trial

ChatGPT in medicine: STAT answers readers' burning questions

Readout Newsletter: Acadia, Eli Lilly, Madrigal Pharma updates

Medical leaders decry Supreme Court decision on affirmative action

Readout Newsletter: Novavax stock, FogPharma, Novo Nordisk

The high cost of giving birth even with insurance

In his State of the Union, Biden takes clear aim at 'Big Pharma'

Wikipedia

Readout Newsletter: Acadia, Eli Lilly, Madrigal Pharma updates

Close Medicare's dangerous gaps in addiction treatment coverage

Just how do doctors, lawmakers, and the public define abortion?

UnitedHealth financials solid despite Change Healthcare cyberattack

Health care needs a new profession: neuroimaging counseling

Cancer researcher Catriona Jamieson is sending tumors into space

entertainment

hotspot

hotspot

entertainment